In adults hospitalized with COVID-19, adding baricitinib vs. dexamethasone to remdesivir did not differ for MV-free survival.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 36191322.
- Also identified by DOI 10.7326/J22-0074.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Wolfe CR, Tomashek KM, Patterson TF, et al. <b>Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.</b> Lancet Respir Med. 2022;10:888-99. 35617986.
Medical subject headings
- COVID-19 Drug Treatment